MOREPENLAB.NS Morepen Laboratories NSE up 18.46% to ₹46.47 on 84.44M: Momentum watch
MOREPENLAB.NS stock surged 18.46% to ₹46.47 on 24 Feb 2026 as trade exploded to 84,438,617.00 shares. The move made Morepen Laboratories Limited one of the day’s most active names on the NSE and pushed volume to roughly 71.15x its average. Price jumped from the prior close of ₹39.23 and set a session high of ₹48.84. Traders cited a combination of heavy flows, short-covering and a low float relative to daily demand. We review valuation, technicals, the Meyka grade, and the near-term outlook.
MOREPENLAB.NS stock: intraday price and volume snapshot
Today MOREPENLAB.NS stock closed at ₹46.47, up 18.46% from ₹39.23. The intraday range was ₹45.28 to ₹48.84. Volume hit 84,438,617.00 versus an average of 1,676,477.00, producing a relative volume of 71.15.
Such a volume spike classifies Morepen as one of the market’s most active issues for the session and explains the sharp price movement.
Valuation and fundamentals for MOREPENLAB.NS stock
Morepen reports EPS of ₹1.76 and a trailing PE of 25.73. Price-to-book is 2.08 and price-to-sales is 1.38. Market capitalization stands near ₹24,811,343,491.00 with 547,953,699.00 shares outstanding.
The company shows a current ratio of 2.23 and debt-to-equity of 0.13, indicating a conservative balance sheet. Compared with Healthcare peers (sector avg PE ~40.75), Morepen looks cheaper on PE and PB metrics.
Technical snapshot and momentum for MOREPENLAB.NS stock
Momentum indicators are stretched: RSI is 69.78, CCI is 353.57, and MFI is 93.67, signaling short-term overbought conditions. MACD shows positive momentum with MACD histogram around 0.60.
The stock trades above its 50-day average (₹38.66), but slightly below the 200-day average (₹49.75). Short-term traders should expect volatile intraday swings given the volume surge and overbought signals.
Sector comparison and drivers for MOREPENLAB.NS stock
Morepen operates in the Healthcare sector, within Drug Manufacturers – Specialty & Generic. The sector’s average PE is roughly 40.75 and average PB is 4.73. Morepen’s lower PE of 25.73 implies relative valuation support versus peers.
Key business drivers include APIs, branded generics and home-health devices. Exports to about 75 countries and recent product distribution strength help revenue momentum, but margin pressure and working capital cycles matter.
Meyka AI rates MOREPENLAB.NS with a score out of 100
Meyka AI rates MOREPENLAB.NS with a score out of 100: 74.26 / 100, Grade B+, Suggestion BUY. This grade factors S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts and analyst signals.
This proprietary grade is informational only. It does not guarantee outcomes and is not personalized financial advice.
Price outlook, forecasts and risks for MOREPENLAB.NS stock
Meyka AI’s forecast model projects a one-year target of ₹61.83, implying an upside of 33.05% versus the current ₹46.47. The model also shows a monthly projection of ₹28.56, underlining near-term volatility.
Risks include stretched technicals, earnings rhythm (next earnings on 11 May 2026), and episodic volume-driven spikes. Investors should weigh the forecast against high intraday volatility and limited short-term liquidity depth despite heavy trading today.
Final Thoughts
Key takeaways on MOREPENLAB.NS stock: today’s 18.46% rise to ₹46.47 was driven by exceptional volume of 84,438,617.00 shares, which made the stock one of the most active names on the NSE. Fundamentals show EPS ₹1.76, PE 25.73, and a conservative debt-to-equity of 0.13, leaving room vs. healthcare peers on valuation. Technical indicators are overbought, so short-term retracement risk is real. Meyka AI’s forecast model projects ₹61.83 in 12 months, implying 33.05% upside from today; forecasts are model-based projections and not guarantees. Traders focused on momentum can use tighter stops, while longer-term investors should monitor earnings on 11 May 2026 and wait for confirmation of sustainable volume and margin improvements before adding exposure. Meyka AI provided the grade and forecast as part of its AI-powered market analysis platform.
FAQs
What caused the surge in MOREPENLAB.NS stock today?
A large volume spike to 84,438,617.00 shares and heavy buying pushed the price to ₹46.47, up 18.46%. Market flows, short-covering and momentum trading were primary drivers.
How is MOREPENLAB.NS valued versus peers?
Morepen trades at PE 25.73 and PB 2.08, below the Healthcare sector PE of about 40.75, suggesting relative valuation support compared with peers.
What is Meyka AI’s price forecast for MOREPENLAB.NS stock?
Meyka AI’s model projects ₹61.83 in one year, implying about 33.05% upside from the current ₹46.47. Forecasts are model projections and not guarantees.
Is MOREPENLAB.NS a high-risk trade after today’s move?
Yes. Technicals show RSI 69.78 and MFI 93.67, suggesting overbought conditions. High intraday volume adds volatility, increasing short-term risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.